Accuvest Global Advisors Takes Position in Johnson & Johnson (JNJ)

Share on StockTwits

Accuvest Global Advisors bought a new position in Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,691 shares of the company’s stock, valued at approximately $1,063,000.

Several other hedge funds and other institutional investors also recently modified their holdings of JNJ. Selective Wealth Management purchased a new position in shares of Johnson & Johnson during the third quarter valued at $105,000. WP Advisors LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at $108,000. Fusion Family Wealth LLC grew its holdings in shares of Johnson & Johnson by 621.4% during the second quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock valued at $123,000 after buying an additional 870 shares in the last quarter. First Capital Advisors Group LLC. purchased a new position in shares of Johnson & Johnson during the third quarter valued at $207,000. Finally, Jentner Corp purchased a new position in shares of Johnson & Johnson during the third quarter valued at $208,000. Institutional investors and hedge funds own 68.98% of the company’s stock.

In other Johnson & Johnson news, VP Peter Fasolo sold 166,695 shares of the business’s stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $146.41, for a total value of $24,405,814.95. Following the completion of the sale, the vice president now owns 155,540 shares of the company’s stock, valued at $22,772,611.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Alex Gorsky sold 264,465 shares of the business’s stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $145.96, for a total value of $38,601,311.40. Following the completion of the sale, the chief executive officer now directly owns 481,254 shares of the company’s stock, valued at approximately $70,243,833.84. The disclosure for this sale can be found here. Insiders sold 465,746 shares of company stock valued at $67,951,916 in the last ninety days. Insiders own 0.22% of the company’s stock.

Shares of NYSE:JNJ opened at $134.45 on Thursday. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99. The stock has a market capitalization of $355.22 billion, a price-to-earnings ratio of 16.44, a P/E/G ratio of 2.11 and a beta of 0.68. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.02. Johnson & Johnson had a return on equity of 35.09% and a net margin of 18.75%. The company had revenue of $20.39 billion during the quarter, compared to analysts’ expectations of $20.27 billion. During the same quarter in the previous year, the firm earned $1.74 earnings per share. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 8.57 EPS for the current fiscal year.

Johnson & Johnson declared that its board has authorized a stock repurchase program on Monday, December 17th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the company to reacquire up to 1.5% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 12th. Shareholders of record on Tuesday, February 26th will be given a $0.90 dividend. The ex-dividend date of this dividend is Monday, February 25th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.68%. Johnson & Johnson’s dividend payout ratio is currently 44.01%.

JNJ has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Wells Fargo & Co reissued an “outperform” rating and set a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Raymond James lifted their price objective on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Credit Suisse Group lifted their price objective on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Finally, Citigroup lifted their price objective on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $142.20.

ILLEGAL ACTIVITY WARNING: “Accuvest Global Advisors Takes Position in Johnson & Johnson (JNJ)” was first reported by BBNS and is owned by of BBNS. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://baseballnewssource.com/2019/02/14/accuvest-global-advisors-takes-position-in-johnson-johnson-jnj/3214705.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Stock Symbol

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.